G1 Therapeutics, Inc. provided Financial Guidance for the full year 2023. For the period, the company expects to generate between $50 million and $60 million in COSELA net revenue in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | +1.35% | -8.79% | -1.31% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.31% | 155M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- GTHX Stock
- News G1 Therapeutics, Inc.
- G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023